Compare Revvity Inc (RVTY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Tapestry, Inc. — how do they compare? Revvity Inc trades at $155.04 (market cap $16.98B), while Tapestry, Inc. trades at $116.26 (market cap $23.09B). The key difference: Tapestry, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays the higher dividend (1.6%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Tapestry, Inc. for 70 Days on average.
| RVTY | TPR | |
|---|---|---|
Market Cap | $16.98B | $23.09B |
Volume | 1,456,900 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $157.36 | $164.78 |
52-Week Low | $82.26 | $98.81 |
Typical Hold Time | 12 Days | 70 Days |
Enterprise Value | $19.30B | $25.89B |
Dividend Yield | 0.18% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
TPR trades at $116.26, up 2.53% today, with a bearish technical signal but strong analyst consensus. Recent earnings beats and a high ROE of 197.14% highlight operational strength, though net income margin fell sharply in 2025. The stock is supported by a $174.64 consensus price target and positive news on international growth, but faces risks from tariffs and Kate Spade execution challenges.
Outlook remains positive with 73% buy ratings and projected revenue growth to $8.0B in 2026. Key opportunities include margin expansion and Coach brand momentum, while risks involve volatile cash flows, high debt, and competitive pressures. The current price offers a 50% upside to the consensus target, but investors should monitor earnings delivery and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
